Wednesday, 14 January 2026
| Wednesday, 14 January 2026 | |
|---|---|
| 8:00 – 17:00 | Poster Hall Setup |
| 9:00 – 20:30 | Registration Opens |
| 12:00 – 16:00 | Oxford Toxins 101 |
| 18:00 – 18:30 | Auditorium Welcome and Opening Remarks David Simpson, MD (USA) |
| 18:30 – 19:30 | Managing Musician’s Dystonia with Botulinum Neurotoxin: The Clinical and Personal Performance Journey A special session with physicians and their patients, including musical performance Pedro Garcia Ruiz, MD (Spain) David Simpson, MD (USA) Anna Castagna, MD (Italy) |
| 19:30 – 21:30 | Roma-Milan-Venecia Welcome Reception Poster and Exhibit Hall Open |
| Thursday, 15 January 2026 | |
|---|---|
| 7:00 – 18:30 | Registration/Information |
| 7:30 – 8:30 | Breakfast Poster and Exhibit Hall Open |
| 8:30 – 12:15 | Auditorium Plenary Session Chair: David Simpson, MD (USA) |
| 8:30 – 8:45 | Opening remarks David Simpson, MD (USA) Introduction of keynote speaker Giampietro Schiavo, PhD, FMedSci, FRSB (UK) |
| 8:45 – 9:45 | The uniqueness of the human neuron Pierre Vanderhaeghen, MD, PhD (Belgium) |
| 9:45 – 10:15 | How BoNT/A enters the neuron: Understanding the mechanisms of translocation Richard A. Kammerer, PhD (Switzerland) |
| 10:15 – 10:55 | Break Poster and Exhibit Hall Open |
| 10:55 – 11:45 | Analog vs Digital Using phenomenology and artificial intelligence/technology in the diagnosis of hyperkinetic movement disorders and its phenotypes Moderator: Joseph Jankovic, MD (USA) Phenomenology (video-case based) Jörg Wissel, MD, FRCP (Germany) Dx Incorporating Artificial Intelligence (AI) Chi Wang Ip, MD (Germany) |
| 11:45 – 12:15 | Pathophysiology of muscle changes in patients with spasticity (including myopathy) Rajiv Reebye, MD, FRCPC (Canada) |
| 12:15 – 14:15 | Lunch Poster and Exhibit Hall Open |
| Time | Basic Science Track Oxford |
Time | Clinical Track 1A Toulousse-Lyon |
Time | Clinical Track 2A Munich-Frankfurt |
Time | Clinical Track 3A Estraburgo-Burdeos |
Time | Clinical Track 4A Paris |
Time | Clinical Track 5A Colonia-Dusseldorf |
Time | Clinical Track 6A Marsella |
Time | Clinical Track 7A Auditorium |
Time | Clinical Track 8A Baden Baden-Dresden-Stuttgard |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14:15 – 15:45 | BoNT-Complex Architecture and Novel BoNT-Like Toxins Chair: Min Dong, PhD (USA) Co-Chair: Ornella Rossetto, PhD (Italy) |
14:15 – 15:45 | Adult Spasticity I Chair: Alberto Esquenazi, MD (USA) |
14:15 – 15:45 | Aesthetics and Dermatology I Chair: Doris Hexsel, MD (Brazil) |
14:15 – 15:45 | Hot Topics in BoNT Therapy Chair: Chris Boulias, MD, PhD (Canada) |
14:15 – 15:45 | Sialorrhea Chair: Wolfgang Jost, MD (Germany) |
14:15 – 15:45 | Use of BoNTs in Urology/Gastroenterology Chair: Dudley Robinson, MBBS, MD, FRCOG (UK) |
14:15 – 15:45 | Ultrasound: Lower Limb Chair: Katharine Alter, MD (USA) |
14:15 – 15:15 | Injection Demonstration Workshop: Cervical Dystonia Moderator: Hubert Fernandez, MD (USA) Moderator: Alberto Albanese, MD (Italy) |
14:15 – 15:15 | Injection Demonstration Workshop: Vocal Dystonia and Voice Disorders Moderator: Andrew Blitzer, MD, DDS (USA) Moderator: Nikita Kohli, MD (USA) |
|||||||||||
| 14:15 – 14:35 | BoNT exploit host proteases to boost their oral toxicity via activating OrfX/P47 Rongsheng Jin, PhD (USA) |
14:15 – 14:55 | A pragmatic approach to treating upper and lower limb spasticity Jörg Wissel, MD, FRCP (Germany) Bo Biering-Sørensen, MD, MPG (Denmark) |
14:15 – 14:55 | Where to inject botulinum toxin for aesthetics: An anatomical analysis Nowell Solish, MD (Canada) |
14:15 – 14:40 | Dosage conversion among different BTX preparations: Is there pharmacological evidence? Joaquim Ferreira, MD, PhD (Portugal) |
14:15 – 14:40 | Sialorrhea: Etiology, assessment, and an overview of clinical management Wolfgang Jost, MD (Germany) |
14:15 – 14:35 | Management of refractory OAB Dudley Robinson, MBBS, MD, FRCOG (UK) |
14:15 – 15:45 | Katharine Alter, MD (USA) Atul Patel, MD (USA) Omar Khan, MD, FRCPC (Canada) Panagiotis Kassavetis, MD, PhD (USA) Ann Ly, MD (USA) Emmanuel Akano, MD (USA) Sebastian Schroeder, MD (Germany) Klemen Grabljevec, MD (Slovenia) Steffen Berweck, MD (Switzerland) Yeva Fernandez, MD (USA) |
14:15 – 15:15 | Local Injectors: Juan Carlos Martinez-Castrillo, MD (Spain) Araceli Alonso Cánovas MD, PhD (Spain) |
14:15 – 15:15 | Local Injectors: Pedro Garcia Ruiz, MD (Spain) Carlos Cenjor, MD (Spain) |
|||||||||||
| 14:35 – 14:55 | Structure of the complete 14-subunit botulinum neurotoxin B complex reveals a unique anchoring through the narrow central pore of HA70 Paul Stenmark, PhD (Sweden) |
14:40 – 15:00 | Clinical relevance of neutralizing antibodies Philipp Albrecht, MD (Germany) |
14:35 – 14:55 | Botox beyond the bladder: Other uses of botulinum toxin in the pelvis Philip Toozs-Hobson, MD (UK) |
|||||||||||||||||||||||
| 14:55 – 15:15 | M-PTC/HA70 complex structure Andreas Rummel, PhD (Germany) |
14:55 – 15:20 | The long-term adherence challenge – analysis of a non-intervention of BoNT-A over more than 10 years Jorge Jacinto, MD (Portugal) |
14:55 – 15:20 | Correcting asymmetries: Aesthetic botulinum toxin techniques in therapeutic patients Alessandra Grassi Salles, MD, PhD (Brazil) |
15:00 – 15:25 | Adherence and dropout in BoNT therapy David Simpson, MD (USA) |
14:40 – 15:05 | Dosing strategies and long-term use of botulinum toxin for the management of Sialorrhea Heakyung Kim, MD (USA) |
14:55 – 15:15 | Use of botulinum toxin in the neurogenic population Francisco Cruz, PhD (Portugal) |
Time | Clinical Track 7B – Part 1 Baden Baden-Dresden-Stuttgard |
Time | Clinical Track 8B – Part 1 Auditorium |
|||||||||||||
| 15:15 – 15:35 | The Expanding Family of BoNT-like Toxins: Evolution, Diversity, and Function Andrew C. Doxey, PhD (Canada) |
15:20 – 15:45 | Pain reduction with repeated injections of botulinum toxin A in upper limb spasticity: A longitudinal analysis from the ULIS-III Study Jorge Jacinto, MD (Portugal) |
15:20 – 15:45 | New Botulinum Toxin Type E for Rapid Onset and Short Duration for the treatment of Glabellar Lines: Results from the clinical trials Steve Yoelin, MD (USA) |
15:25 – 15:35 | Physician Assessment of Non-Medical Toxin Switching on Patient Care David Charles, MD (USA) |
15:05 – 15:30 | Japanese multicenter study of incobotulinum toxin for sialorrhea Noriko Nishikawa, MD, PhD (Japan) |
15:15 – 15:35 | Emerging roles for botulinum toxin in urology and urogynecology Christopher Chermansky, MD (USA) |
15:15 – 15:45 | Injection Demonstration Workshop: Challenging BoNT Cases: Treating Patients with Multiple Conditions Moderator: Hubert Fernandez, MD (USA) Moderator: Robert Chen, MD (Canada) |
15:15 – 15:45 | Injection Demonstration Workshop: Cranial Dystonia (Meige, Hemifacial Spasm and Blepharospasm) Moderator: Francisco Cardoso, MD (Brazil) Moderator: Barbara Karp, MD (USA) |
|||||||||||||
| 15:35 – 15:45 | Identification and Characterization of Botulinum Neurotoxin-like Two-Component Toxins in Paeniclostridium ghonii Pyung-Gang Lee, PhD (USA) |
15:30 – 15:45 | Panel Discussion | 15:35 – 15:45 | Panel Discussion (Q&A) |
15:15 – 15:45 | Local Injector: Pedro Garcia-Ruiz, MD (Spain) |
15:15 – 15:45 | Local Injectors: Rocio Garcia Ramos, MD (Spain) Eva Lopez Valdes, MD (Spain) |
|||||||||||||||||||
| 15:45 – 16:25 | Break Poster and Exhibit Hall Open |
15:45 – 16:25 | Break Poster and Exhibit Hall Open |
15:45 – 16:25 | Break Poster and Exhibit Hall Open |
15:45 – 16:25 | Break Poster and Exhibit Hall Open |
15:45 – 16:25 | Break Poster and Exhibit Hall Open |
15:45 – 16:25 | Break Poster and Exhibit Hall Open |
15:45 – 16:25 | Break Poster and Exhibit Hall Open |
15:45 – 16:25 | Break Poster and Exhibit Hall Open |
15:45 – 16:25 | Break Poster and Exhibit Hall Open |
15:45 – 16:25 | Break Poster and Exhibit Hall Open |
|||||||||
| Time | Basic Science Track Oxford |
Time | Clinical Track 1B Toulousse-Lyon |
Time | Clinical Track 2B Munich-Frankfurt |
Time | Clinical Track 3B Estraburgo-Burdeos |
Time | Clinical Track 4B Paris |
Time | Clinical Track 6B Marsella |
Time | Clinical Track 7B – Part 2 Baden Baden-Dresden-Stuttgard |
Time | Clinical Track 8B – Part 2 Auditorium |
Time | Clinical Track 9B Colonia-Dusseldorf |
|||||||||||
| 16:25 – 18:00 | Structural and Functional Aspects of Clostridial Neurotoxins Chair: Frederic A. Meunier, PhD (Australia) Co-Chair: Marco Pirazzini, PhD (Italy) |
16:25 – 17:55 | Spasticity II Chair: Jörg Wissel, MD, FRCP (Germany) |
16:25 – 17:55 | Aesthetics & Dermatology Workshop II Chair: Nowell Solish, MD (Canada) |
16:25 – 17:55 | Tics and Tremor Chair: Joseph Jankovic, MD (USA) |
16:25 – 17:55 | Pediatric Spasticity (and Other Conditions for BoNT Relative to the Pediatric Patient) Chair: Mark Gormley, MD (USA) |
16:25 – 17:55 | Ultrasound Workshop: Upper Limb Chair: Katharine Alter, MD (USA) |
16:25 – 16:55 | Injection Demonstration Workshop: Challenging BoNT Cases: Treating Patients with Multiple Conditions Moderator: Hubert Fernandez, MD (USA) Moderator: Robert Chen, MD (Canada) |
16:25 – 16:55 | Injection Demonstration Workshop: Cranial Dystonia (Meige, Hemifacial Spasm and Blepharospasm) Moderator: Francisco Cardoso, MD (Brazil) Moderator: Barbara Karp, MD (USA) |
16:25 – 17:55 | Injection Demonstration Workshop: Urology/Urogynecology Moderator: Dudley Robinson, MBBS, MD, FRCOG (UK) Moderator: Francisco Cruz, PhD (Portugal) |
|||||||||||
| 16:25 – 16:45 | Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A Atsushi Yamagata, PhD (Japan) |
16:25 – 16:50 | Botulinum toxin for post-stroke spasticity: Experience in the developing world Tae Mo Chung, MD (Brazil) |
16:25 – 17:05 | Voyage to Beauty and Wellness Jean Carruthers, MD (USA) |
16:25 – 17:05 | Botulinum toxin for treating tic disorder: Case series presentation Joseph Jankovic, MD (USA) Heakyung Kim, MD (USA) |
16:25 – 16:50 | Update on the use of botulinum toxin in pediatric patients Mark Gormley, MD (USA) |
16:25 – 17:55 | Katharine Alter, MD (USA) Atul Patel, MD (USA) Panagiotis Kassavetis, MD, PhD (USA) Ann Ly, MD (USA) Emmanuel Akano, MD (USA) Sebastian Schroeder, MD (Germany) Klemen Grabljevec, MD (Slovenia) Steffen Berweck, MD (Switzerland) Serdar Koçer, MD (Switzerland) Yeva Fernandez, MD (USA) |
16:25 – 16:55 | Local Injectors: Juan Carlos Martinez-Castrillo, MD (Spain) Araceli Alonso Cánovas MD, PhD (Spain) |
16:25 – 16:55 | Local Injectors: Pedro Garcia Ruiz, MD (Spain) Lola Martinez Perez, MD (Spain) Rocio Garcia Ramos, MD (Spain) Eva Lopez Valdes, MD (Spain) |
16:25 – 17:55 | Local Injectors: Raquel González López, MD (Spain) Hector Garde Garcia, MD (Spain) |
|||||||||||
| 16:45 – 17:05 | Structures of native SV2A reveal the binding mode for tetanus neurotoxin and anti-epileptic racetams Janine Brunner, PhD (Belgium) |
|||||||||||||||||||||||||||
| 17:05 – 17:25 | Retrograde transport and membrane translocation at the ER Frederic Bard, PhD (Singapore) |
16:50 – 17:15 | Chronic vs acute spasticity in adults: What are the options to maximize treatment goals? Cindy B. Ivanhoe, MD (USA) |
17:05 – 17:30 | Ten Tips and Tricks After Injecting Toxins in An Aesthetic Practice for Over 25 Years Steve Yoelin, MD (USA) |
16:50 – 17:15 | The special challenges of pediatric spasticity Rajiv Reebye, MD, FRCPC (Canada) |
Time | Clinical Track 7C Baden Baden-Dresden-Stuttgard |
Time | Clinical Track 8C Auditorium |
|||||||||||||||||
| 17:25 – 17:35 | Low-dose intestinal exposure to botulinum neurotoxins increases susceptibility to Salmonella and Shigella infection Federico Fabris, PhD (Italy) |
17:15 – 17:40 | Beyond BoNT: Other injectables and treatments for patients with spasticity Omar Khan, MD, FRCPC (Canada) |
17:30 – 17:55 | Ethnic and cultural considerations in facial aesthetics: Optimizing patient assessment, satisfaction, and outcomes with botulinum toxin Wendy Lee, MD (USA) |
17:15 – 17:35 | BoNT for essential tremor: New data from placebo-controlled trials David Simpson, MD (USA) |
17:15 – 17:40 | Spasticity management through neurolysis and or minimally-invasive neuro-orthopedics – focus on the pediatric patient Jonathan Bemporad, MD (Italy) |
16:55 – 17:55 | Injection Demonstration Workshop: Occupational and Focal Limb Dystonia (Writers Cramp) Moderator: Hubert Fernandez, MD (USA) Moderator: Robert Chen, MD (Canada) |
16:55 – 17:55 | Injection Demonstration Workshop: Headache & Pain Moderator: Bahman Jabbari, MD (USA) Moderator: Barbara Karp, MD (USA) |
|||||||||||||||
| 17:35 – 17:45 | Pre-synaptic terminal proteins and nicotinic receptors are depleted from mouse parasympathetic ganglionic junctions paralysed with botulinum neurotoxin type A Gary Lawrence, BSc, DIC, PhD (Ireland) |
|||||||||||||||||||||||||||
| 17:45 – 17:55 | Crystal structure of the catalytic domain of BoNT/X in complex with its substrate, VAMP2 Sara Persson Kosenina, PhD (Sweden) |
17:40 – 17:55 | Multimodal Imaging Biomarkers for the Evaluation and Management of Spasticity: Magnetic Resonance Imaging, B-mode Ultrasound, and Shear Wave Elastography Jelena Simic, MD (Norway) |
17:35 – 17:55 | Managing tremor and other symptoms in patients with Parkinson’s disease Sanjay Pandey, MD (India) |
17:40 – 17:55 | IncobotulinumtoxinA for the Treatment of Lower Limb Spasticity in Children and Adolescents with Cerebral Palsy: Evaluation of Lower Limb IncobotulinumtoxinA Efficacy (ELLIE) Sebastian Schroeder, MD (Germany) |
16:55 – 17:55 | Local Injector: Pedro Garcia Ruiz, MD (Spain) Lydia Lopez Manzanares, MD (Spain) |
16:55 – 17:55 | Local Injectors: Jaime Rodriguez-Vico, MD (Spain) Paloma Valin VIllanueva, MD (Spain) |
|||||||||||||||||
| 18:00 – 19:00 | Oxford INA Business Meeting |
18:00 – 19:00 | Oxford INA Business Meeting |
18:00 – 19:00 | Oxford INA Business Meeting |
18:00 – 19:00 | Oxford INA Business Meeting |
18:00 – 19:00 | Oxford INA Business Meeting |
18:00 – 19:00 | Oxford INA Business Meeting |
18:00 – 19:00 | Oxford INA Business Meeting |
18:00 – 19:00 | Oxford INA Business Meeting |
18:00 – 19:00 | Oxford INA Business Meeting |
| Friday, 16 January 2026 | |
|---|---|
| 7:00 – 18:30 | Registration/Information |
| 7:30 – 8:30 | Breakfast Poster and Exhibit Hall Open |
| 8:30 – 12:00 | Auditorium Plenary Session Chair: Giampietro Schiavo, PhD, FMedSci, FRSB (UK) |
| 8:30 – 8:45 | Welcome Back David Simpson, MD (USA) |
| 8:45 – 9:20 | Neuroplasticity and the mechanisms of chronic pain David Bennett, MD (UK) |
| 9:20 – 9:50 | Neurotoxins in the management of pain: Where are we and where are we going? David Simpson, MD (USA) |
| 9:50 – 10:20 | Perineural BTX-A treatment – A new way of treating neuropathic pain? Bo Biering-Sørensen, MD, MPG (Denmark) |
| 10:20 – 11:00 | Break Poster and Exhibit Hall Open |
| 11:00 – 11:30 | A look into the future: BoNT in cancer therapy Gustavo Ayala, MD (USA) |
| 11:30 – 12:00 | The clinical utility of botulinum toxin in wound healing (BoNT-A and BoNT-E) David Ozog, MD (USA) |
| 12:00 – 14:00 | Lunch Poster and Exhibit Hall Open |
| Time | Basic Science Track Oxford |
Time | Clinical Track 1A Colonia-Dusseldorf |
Time | Clinical Track 2A Toulousse-Lyon |
Time | Clinical Track 3A Londres-Bristol |
Time | Clinical Track 4A Munich-Frankfurt |
Time | Clinical Track 5A Baden Baden-Dresden-Stuttgard |
Time | Clinical Track 6A Marsella |
Time | Clinical Track 7A Auditorium |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14:00 – 15:30 | Genetics and Engineering of BoNTs Chair: Carolina Luquez, PhD (USA) Co-Chair: Paul Stenmark, PhD (Sweden) |
14:00 – 15:30 | Aesthetics and Dermatology III Chair: Nowell Solish, MD (Canada) |
14:00 – 15:30 | Cervical Dystonia Chair: Raymond Rosales, MD, PhD (Philippines) |
14:00 – 15:30 | Selected Topics Chair: Bo Biering-Sørensen, MD, MPG (Denmark) |
14:00 – 15:30 | Migraine and Headache Chair: Cristina Tassorelli, MD (Italy) |
14:00 – 15:30 | Hemifacial Spasm, Blepharospasm and Meige Syndrome Chair: Francisco Cardoso, MD (Brazil) |
14:00 – 15:30 | Ultrasound of the Head and Neck Chair: Katharine Alter, MD (USA) |
14:00 – 15:30 | Injection Demonstration Workshop: Adult Spasticity Moderator: Anthony Ward, MBE, BSc, MD, FRCP (UK) Moderator: Cindy B. Ivanhoe, MD (USA) |
||||||||||
| 14:00 – 14:20 | Genetic engineering of novel BoNTs using Spycatcher bonding Bazbek Davletov, PhD (UK) |
14:00 – 14:25 | "Only Tox" for facial rejuvenation – how far can you get with botulinum toxin alone Patricia Ogilvie, MD (Germany) |
14:00 – 14:25 | Anatomic structures in the neck: Targeting strategies for cervical dystonia – ultrasound and EMG Alexandre Kreisler, MD, PhD (France) |
14:00 – 14:25 | Is there a role for botulinum toxin in the management of paratonia? Galit Kleiner, MD, FRCPC (Canada) |
14:00 – 14:30 | Have we learned anything new about the pathophysiology of migraine and headache? Rami Burstein, PhD (USA) |
14:00 – 14:25 | Clinical presentation of cranial dystonia and common mimics Hyder (Buz) Jinnah, MD, PhD (USA) |
14:00 – 15:30 | Katharine Alter, MD (USA) Heakyung Kim, MD (USA) Barbara Karp, MD (USA) Atul Patel, MD (USA) Omar Khan, MD, FRCPC (Canada) Hubert Fernandez, MD (USA) Panagiotis Kassavetis, MD, PhD (USA) Ann Ly, MD (USA) Emmanuel Akano, MD (USA) Steffen Berweck, MD (Switzerland) Yeva Fernandez, MD (USA) |
14:00 – 15:30 | Local Injectors: José López Araujo, MD (Spain) Raquel Cutillas, MD (Spain) |
||||||||||
| 14:20 – 14:40 | Development and Optimization of Genetic Manipulation Systems in Group I Clostridium botulinum Sho Amatsu, PhD (USA) |
14:25 – 14:50 | Long-term effects of botulinum toxin Doris Hexsel, MD (Brazil) |
14:25 – 14:50 | Duration of botulinum toxin efficacy in cervical dystonia clinical trials: A scoping review Alberto Albanese, MD (Italy) |
14:25 – 14:50 | Botulinum toxin as a treatment for depression – the BONAFIDE project M. Axel Wollmer, MD (Germany) |
14:30 – 14:55 | Botulinum toxin vs CGRP-targeting monoclonal antibodies: competition or synergy? Patricia Pozo-Rosich, MD, PhD (Spain) |
14:25 – 14:50 | Comparison of botulinum toxin injection techniques: Approach to blepharospasm vs. hemifacial spasm Débora Maia, MD (Brazil) |
||||||||||||||
| 14:40 – 15:00 | Probing the properties of PTEN specific botulinum toxin type E mutants Thomas Binz, PhD (Germany) |
||||||||||||||||||||||||
| 15:00 – 15:10 | Utilizing a Novel Botulinum Toxin to Investigate Intracellular Trafficking Amber Robinson, Mres (UK) |
14:50 – 15:15 | Botulinum toxin Type E in Aesthetics Michael Kane, MD (USA) |
14:50 – 15:15 | Capturing the "yo-yo" effect of botulinum toxin therapy: An app-based patient-centered outcome tool to improve treatment outcomes in cervical dystonia Sarah Pirio-Richardson, MD, FAAN (USA) |
14:50 – 15:15 | Incidence of Spasticity is high in prolonged disorders of consciousness (PDOC): Is there a role for botulinum toxin in the management of nursing, discomfort and pain? Nathalie Draulans, MD (Netherlands) |
14:55 – 15:20 | Post-traumatic headache: Is there a role for botulinum toxin? Lanfranco Pellesi, MD, PhD (Denmark) |
14:50 – 15:15 | The variable phenomenology of Meige syndrome Francisco Cardoso, MD (Brazil) |
||||||||||||||
| 15:10 – 15:20 | Botulinum Neurotoxin A Mutants with Enhanced Ganglioside Binding Show Improved Potency and Altered Ganglioside Selectivity Geoffrey Masuyer, PhD (Sweden) |
||||||||||||||||||||||||
| 15:20 – 15:30 | The Membrane Localization Domain (MLD) of Botulinum Neurotoxin A1 is Essential for Its Long Duration of Action Miriam Guevara, MS (USA) |
15:15 – 15:30 | Panel Discussion (Q&A) |
15:15 – 15:30 | Longitudinal Comparison of BoNT Dose Development Across Different Preparations in Patients With Cervical Dystonia Vera Bertsch (Germany) |
15:15 – 15:30 | Electromyography-guided unilateral botulinum toxin injection for retrograde cricopharyngeus dysfunction (R-CPD): dose effects, sex differences, and clinical-neurophysiological correlates Giuseppe Cosentino, MD (Italy) |
15:20 – 15:30 | Panel Discussion |
15:15 – 15:30 | Optimizing Hemifacial Spasm Management with Botulinum Toxin: A Moroccan Perspective Abderrazak Hajjioui, MD, PhD (Morocco) |
||||||||||||||
| 15:30 – 16:15 | Break Poster and Exhibit Hall Open |
15:30 – 16:15 | Break Poster and Exhibit Hall Open |
15:30 – 16:15 | Break Poster and Exhibit Hall Open |
15:30 – 16:15 | Break Poster and Exhibit Hall Open |
15:30 – 16:15 | Break Poster and Exhibit Hall Open |
15:30 – 16:15 | Break Poster and Exhibit Hall Open |
15:30 – 16:15 | Break Poster and Exhibit Hall Open |
15:30 – 16:15 | Break Poster and Exhibit Hall Open |
15:30 – 16:15 | Break Poster and Exhibit Hall Open |
||||||||
| Time | Basic Science Track Oxford |
Time | Clinical Track 1B Colonia-Dusseldorf |
Time | Clinical Track 2B Toulousse-Lyon |
Time | Clinical Track 3B Londres-Bristol |
Time | Clinical Track 4B Munich-Frankfurt |
Time | Clinical Track 6B Marsella |
Time | Clinical Track 7B Auditorium |
Time | Clinical Track 8B Baden Baden-Dresden-Stuttgard |
||||||||||
| 16:15 – 17:55 | Detection and Countermeasures Chair: Sabine Pellett, PhD (USA) Co-Chair: Suzanne Kalb, PhD (USA) |
16:15 – 17:45 | Pain Chair: Nadine Attal, MD, PhD (France) Chair: Bahman Jabbari, MD (USA) |
16:15 – 17:45 | Telehealth and Artificial Intelligence Technology and Devices: Striving to Improve Patient Care Chair: Jorge Jacinto, MD (Portugal) |
16:15 – 17:45 | Focal Limb Dystonia and Tremor Chair: Alberto Albanese, MD (Italy) |
16:15 – 17:45 | Oromandibular Dystonia and Spasmodic Dysphonia Moderator: Andrew Blitzer, MD, DDS (USA) |
16:15 – 17:45 | Ultrasound of the Head and Neck, Upper and Lower Limb Chair: Katharine Alter, MD (USA) |
16:15 – 17:45 | Injection Demonstration Workshop: Aesthetics and Dermatology Moderator: Steve Yoelin, MD (USA) Moderator: Patricia Ogilvie, MD (Germany) |
16:15 – 17:45 | Injection Demonstration Workshop: Spasticity and other Conditions in Pediatric Patients Moderator: Florian Heinen, MD (Germany) Moderator: Darcy Fehlings, MD (Canada) |
||||||||||
| 16:15 – 16:35 | The degradation of botulinum neurotoxin light chains using PROTACs Patrick McNutt, PhD (USA) |
16:15 – 16:35 | Placebo vs nocebo mechanisms in treating pain: Implications for trials and clinical care Katja Wiech, MD (UK) |
16:15 – 17:05 | Telehealth strategies: Present and near-future realities to enhance patient centric care, adherence and outcomes Health Apps and AI to enhance Therapeutic Alliance Jorge Jacinto, MD (Portugal) How can future apps enhance co-creation, self-management, and collaboration between the primary and secondary healthcare sectors to optimize patient care and treatment outcomes? Bo Biering-Sørensen, MD, MPG (Denmark) Reimagining Rehabilitation: AI-Driven Telerehabilitation for the Future of Patient Care Isabel de Amorim, MD (Portugal) Q&A Discussion |
16:15 – 16:40 | Ultrasound targeting for upper limb dystonia Alexandre Kreisler, MD, PhD (France) |
16:15 – 16:40 | Oromandibular Dystonia: Diagnosis, management and injection techniques Roongroj Bhidayasiri, MD (Thailand) |
16:15 – 17:45 | Katharine Alter, MD (USA) Heakyung Kim, MD (USA) Barbara Karp, MD (USA) Atul Patel, MD (USA) Hubert Fernandez, MD (USA) Panagiotis Kassavetis, MD, PhD (USA) Ann Ly, MD (USA) Emmanuel Akano, MD (USA) Steffen Berweck, MD (Switzerland) Yeva Fernandez, MD (USA) |
16:15 – 17:45 | Local Injectors: Sofia Ruiz del Cueto, MD (Spain) |
16:15 – 17:45 | Local Injectors: María del Mar García-Romero, MD, PhD (Spain) Miguel Ángel Fernández García, MD (Spain) Marina Ascunce Abad, MD (Spain) |
||||||||||
| 16:35 – 16:55 | Development of an European Equine Tetravalent Botulism Antitoxin and Novel Purified F(ab’)2 Botulinum Type A, B, E and F Antitoxin Reference Materials Jasmin Weisemann, PhD (Germany) |
16:35 – 16:55 | Botulinum toxin for complex regional pain syndromes Areerat Suputtitada, MD (Thailand) |
16:40 – 17:05 | Focus on musician’s dystonia André Lee, MD (Germany) |
16:40 – 17:05 | EMG-guided treatment of spasmodic dysphonia Nikita Kohli, MD (USA) |
||||||||||||||||||
| 16:55 – 17:15 | Neuronal membrane-derived nanodiscs for broad-spectrum neurotoxin detoxification Liangfang Zhang, PhD (USA) |
16:55 – 17:15 | Botulinum toxin in the management of painful musculoskeletal pathologies and sports traumatology Serdar Koçer, MD (Switzerland) |
17:05 – 17:30 | Artificial intelligence and high-tech tools to improve diagnosis and management of spasticity and movement disorders patients Mandar Jog, MD (Canada) |
17:05 – 17:30 | Central plasticity effects of botulinum toxin in focal hand dystonia Aparna Wagle Shukla, MD (USA) |
17:05 – 17:30 | Motor and phonic tics Andrew Blitzer, MD, DDS (USA) |
||||||||||||||||
| 17:15 – 17:35 | Intraneuronal delivery of VHHs to reverse BoNT intoxication Shin-Ichiro Miyashita, PhD (Japan) |
17:15 – 17:35 | Neuropathic pain: an update on the utility of botulinum toxin Nadine Attal, MD, PhD (France) |
17:30– 17:45 | Feasibility Study on the Use of an AI-Supported "Torticollis App" for Digital Movement and Posture Therapy in Isolated Cervical Dystonia Martina Steinboeck, MD (Germany) |
17:30 – 17:45 | Efficacy of IncobotulinumtoxinA (BoNT-A) Injection in Task-Specific Tremors Elizabeth Boyd, MD (Canada) |
17:30 – 17:45 | Panel Discussion |
||||||||||||||||
| 17:35 – 17:45 | A High-Throughput Human Neuromuscular Junction-on-a-Chip Platform to Advance Therapeutic Botulinum Toxin Applications and Countermeasures Development Margaret Magdesian, DO, PhD (Canada) |
17:35 – 17:45 | Panel Discussion (Q&A) |
||||||||||||||||||||||
| 17:45 – 17:55 | A Stable and Effective Vaccine Platform for Multivalent Protection Against Botulinum Neurotoxins A, B, and E Jiafu Wang, PhD (Ireland) |
| Saturday, 17 January 2026 | |
|---|---|
| 7:30 – 12:00 | Information |
| 7:30 – 8:30 | Breakfast Poster and Exhibit Hall Open |
| 9:00 – 12:00 | Auditorium Plenary Session Chair: Katharine Alter, MD (USA) |
| 9:00 – 9:10 | Welcome Back David Simpson, MD (USA) |
| 9:10 – 10:00 | Questions about BoNT you were afraid to ask Moderator: David Simpson, MD (USA) Giampietro Schiavo, PhD, FMedSci, FRSB (UK) Nowell Solish, MD (Canada) Katharine Alter, MD (USA) Ornella Rossetto, PhD (Italy) Bo Biering-Sørensen, MD, MPG (Denmark) Jörg Wissel, MD, FRCP (Germany) |
| 10:00 – 10:10 | Announcement and award of the Best Basic Science Abstract Giampietro Schiavo, PhD, FMedSci, FRSB (UK) |
| 10:10 – 10:20 | Announcement and award of the Best Clinical Abstract Katharine Alter, MD (USA) |
| 10:20 – 10:50 | Once upon a dish: The next frontier in engineering multicellular systems András Lakatos, MD, PhD, MRCP (UK) |
| 10:50 – 11:15 | Clinical Lifetime Achievement Award Presentation & Lecture David Simpson, MD (USA) |
| 11:15 – 11:40 | Basic Science Lifetime Achievement Award Presentation & Lecture Giampietro Schiavo, PhD, FMedSci, FRSB (UK) |
| 11:40 – 12:00 | Closing Remarks Katharine Alter, MD (USA) |